A Phase I Pharmacokinetic and Tolerance Study of 28-Day Regimens of Oral Ganciclovir

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

Not specified

Study Completion Date

February 28, 1995

Conditions

Cytomegalovirus RetinitisHIV Infections

Interventions

DRUG

Ganciclovir

Trial Locations (5)

Cornell Univ Med Ctr, New York

Davies Med Ctr, San Francisco

Mount Zion Med Ctr, San Francisco

Univ of California / San Diego Treatment Ctr, San Diego

San Francisco AIDS Clinic / San Francisco Gen Hosp, San Francisco

All Listed Sponsors

collaborator

Hoffmann-La Roche

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00000668 - A Phase I Pharmacokinetic and Tolerance Study of 28-Day Regimens of Oral Ganciclovir | Biotech Hunter | Biotech Hunter